![Investors](https://www.sinobiopharm.com/userfiles/images/menuKV/20_3.jpg)
Investors
Information Disclosure
-
VOLUNTARY ANNOUNCEMENT - ESG PERFORMANCE RECOGNISED BY S&P GLOBAL AND FTSE RUSSELL2024.07.19
-
VOLUNTARY ANNOUNCEMENT - ACCEPTANCE OF NEW DRUG APPLICATION FOR CATEGORY 1 INNVOATIVE DRUG CULMERCICLIB CAPSULE "CULMERCICLIB (TQB3616)"2024.07.18
-
VOLUNTARY ANNOUNCEMENT - POSITIVE RESULTS ON PHASE III STUDY OF ANLOTINIB HYDROCHLORIDE CAPSULE IN COMBINATION WITH CHEMOTHERAPY FOR FIRST-LINE TREATMENT OF ADVANCED SOFT TISSUE SARCOMA2024.07.16
-
VOLUNTARY ANNOUNCEMENT - ACCEPTANCE OF NEW DRUG APPLICATION FOR CATEGORY 1 INNVOATIVE DRUG ROVADICITINIB TABLET "ROVADICITINIB (TQ05105)"2024.07.15
-
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 30 JUNE 20242024.07.02
-
VOLUNTARY ANNOUNCEMENT - APPROVAL FOR MARKETING OF "LIRAGLUTIDE INJECTION"2024.06.25
-
VOLUNTARY ANNOUNCEMENT - PURCHASE OF SHARES BY CHIA TAI TIANQING UNDER THE SHARE INCENTIVE SCHEME2024.06.20
-
VOLUNTARY ANNOUNCEMENT - COMPLETION OF ISSUANCE OF FIRST TRANCHE OF PANDA BONDS2024.06.20